Skip to content

MaxCyte MXCT Free cash flow margin

Free cash flow margin at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
13.8%-0.2pp
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
15.7%-2.1pp
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-119%-21.2pp
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
-110.5%-14.9pp
Repligen logo
RepligenRGEN
21.2%+6.1pp
TEC
Bio-TechneTECH
22.3%+4.0pp

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Calculated from MaxCyte’s reported figures.

Based on trailing twelve months.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's free cash flow margin?
MaxCyte (MXCT) reported free cash flow margin of -90.9% in Q1 2026.
How has MaxCyte's free cash flow margin changed year-over-year?
MaxCyte's free cash flow margin decreased by 3.9% year-over-year, from -87.5% to -90.9%.
What is the long-term trend for MaxCyte's free cash flow margin?
Over 4 years (2021 to 2025), MaxCyte's free cash flow margin has grown at a 26.5% compound annual growth rate (CAGR), from -42.8% to -109.5%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.